|
1
|
Eramo A, Ricci-Vitiani L, Zeuner A, et al:
Chemotherapy resistance of glioblastoma stem cells. Cell Death
Differ. 13:1238–1241. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dean M: ABC transporters, drug resistance,
and cancer stem cells. J Mammary Gland Biol Neoplasia. 14:3–9.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar
|
|
4
|
Phillips TM, McBride WH and Pajonk F: The
response of CD24(−/low)/CD44+ breast cancer-initiating cells to
radiation. J Natl Cancer Inst. 98:1777–1785. 2006.
|
|
5
|
Tanei T, Morimoto K, Shimazu K, et al:
Association of breast cancer stem cells identified by aldehyde
dehydrogenase 1 expression with resistance to sequential Paclitaxel
and epirubicin-based chemotherapy for breast cancers. Clin Cancer
Res. 15:4234–4241. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Reya T and Clevers H: Wnt signalling in
stem cells and cancer. Nature. 434:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li Y, Welm B, Podsypanina K, et al:
Evidence that transgenes encoding components of the Wnt signaling
pathway preferentially induce mammary cancers from progenitor
cells. Proc Natl Acad Sci USA. 100:15853–15858. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu BY, McDermott SP, Khwaja SS and
Alexander CM: The transforming activity of Wnt effectors correlates
with their ability to induce the accumulation of mammary progenitor
cells. Proc Natl Acad Sci USA. 101:4158–4163. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lowry OH, Rosebrough NJ, Farr AL and
Randall RJ: Protein measurement with the Folin phenol reagent. J
Biol Chem. 193:265–275. 1951.PubMed/NCBI
|
|
10
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Steeg PS: Tumor metastasis: mechanistic
insights and clinical challenges. Nat Med. 12:895–904. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fu Y, Zheng S, An N, et al: β-catenin as a
potential key target for tumor suppression. Int J Cancer.
129:1541–1551. 2011.
|
|
14
|
DiMeo TA, Anderson K, Phadke P, et al: A
novel lung metastasis signature links Wnt signaling with cancer
cell self-renewal and epithelial-mesenchymal transition in
basal-like breast cancer. Cancer Res. 69:5364–5373. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin SY, Xia W, Wang JC, et al:
Beta-catenin, a novel prognostic marker for breast cancer: its
roles in cyclin D1 expression and cancer progression. Proc Natl
Acad Sci USA. 97:4262–4266. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brabletz T, Jung A, Reu S, et al: Variable
beta-catenin expression in colorectal cancers indicates tumor
progression driven by the tumor environment. Proc Natl Acad Sci
USA. 98:10356–10361. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Khan S, Aspe JR, Asumen MG, et al:
Extracellular, cell-permeable survivin inhibits apoptosis while
promoting proliferative and metastatic potential. Br J Cancer.
100:1073–1086. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Woodward WA, Chen MS, Behbod F, Alfaro MP,
Buchholz TA and Rosen JM: WNT/beta-catenin mediates radiation
resistance of mouse mammary progenitor cells. Proc Natl Acad Sci
USA. 104:618–623. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schöler HR, Dressler GR, Balling R,
Rohdewohld H and Gruss P: Oct-4: a germline-specific transcription
factor mapping to the mouse t-complex. EMBO J. 9:2185–2195.
1990.PubMed/NCBI
|
|
20
|
Schöler HR, Ruppert S, Suzuki N, Chowdhury
K and Gruss P: New type of POU domain in germ line-specific protein
Oct-4. Nature. 344:435–439. 1990.PubMed/NCBI
|
|
21
|
Nakanishi T, Chumsri S, Khakpour N, et al:
Side-population cells in luminal-type breast cancer have
tumour-initiating cell properties, and are regulated by HER2
expression and signalling. Br J Cancer. 102:815–826. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nguyen NP, Almeida FS, Chi A, et al:
Molecular biology of breast cancer stem cells: potential clinical
applications. Cancer Treat Rev. 36:485–491. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Abaan OD, Mutlu PK, Baran Y, Atalay C and
Gunduz U: Multidrug resistance mediated by MRP1 gene overexpression
in breast cancer patients. Cancer Invest. 27:201–205. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang JS, Zheng CL, Wang YJ, et al: Gene
silencing of beta-catenin by RNAi inhibits cell proliferation in
human esophageal cancer cells in vitro and in nude mice. Dis
Esophagus. 22:151–162. 2009. View Article : Google Scholar : PubMed/NCBI
|
